RT Journal Article
SR Electronic
T1 Integrated DNA estimation in tissue biopsy and detection in liquid biopsy by HBV-targeted NGS assay
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.12.04.24318256
DO 10.1101/2024.12.04.24318256
A1 Liu, Hsin-Ni
A1 Lin, Selena Y.
A1 Ramirez, Ricardo
A1 Chen, Shin-En
A1 Heimer, Zach
A1 Kubas, Roman
A1 Shieh, Fwu-Shan
A1 Kim, Elena S.
A1 Liu, Yuanjie
A1 Lau, Daryl T.Y.
A1 Chang, Ting-Tsung
A1 Guo, Haitao
A1 Wang, Zhili
A1 Su, Ying-Hsiu
YR 2024
UL http://medrxiv.org/content/early/2024/12/05/2024.12.04.24318256.abstract
AB Background & Aims Integrated HBV DNA (iDNA) plays a critical role in HBV pathogenesis, particularly in predicting treatment response and HCC. This study aimed to use an HBV hybridization-capture next-generation sequencing (HBV-NGS) assay to detect HBV-host junction sequences (HBV-JS) in a sensitive nonbiased manner to detect and estimate the iDNA fraction in tissue biopsies and HBV genetics by liquid biopsy.Methods HBV DNA from plasmid monomers, HBV-HCC cell line (SNU398, Hep3B, and PLC/PRF/5), tissue biopsies of patients with serum HBV DNA <4 log IU/ml, and matched urine and plasma of HBV patients were assessed by HBV-NGS. Junction-specific qPCR (JS-qPCR) assays were developed to quantify abundant HBV-JS.Results We demonstrated high coverage uniformity, reproducibility across all HBV genotypes A-D, and 0.1% sensitivity for detecting iDNA by the HBV-NGS assay. The sequence and structures of iDNA molecules from SNU398 and Hep3B are reported. An iDNA estimation model was developed using six abundant HBV-JS sequences identified from tissue biopsies by HBV-NGS assay and validated using total DNA of SNU398 and Hep3B cells. Furthermore, the utility of the HBV-NGS assay for HBV genetic analysis in liquid biopsies was explored using matched plasma-urine samples from three patients with serum HBV DNA levels ranging from high to undetectable. HBV-JS was detected in all body fluids tested, regardless of viral load.Conclusion These findings suggest that the iDNA fraction in tissue biopsies from patients with limited or undetectable serum HBV DNA can be estimated using a robust HBV-NGS assay, and a sensitive HBV genetics liquid biopsy can be obtained. This study highlights the potential of NGS-based methods to advance HBV management.Impact and implications This study applied an unbiased, sensitive, and robust HBV-captured NGS method to detect integrated HBV DNA (iDNA) in both tissue and liquid (blood and urine) biopsies and generated a model to estimate the intrahepatic iDNA quantity. The availability of this technology makes possible to not only estimate iDNA fraction in total HBV DNA in tissue biopsies, but also perform HBV genetics in a minimally invasive manner in chronic HBV patients for disease monitoring, HCC risk assessment, and for clinical research.Competing Interest StatementSL, ZW, and YS: Shareholder of JBS Science Inc. SL, SC, ZH, RK, FS, and ZW are employees of JBS Science, Inc at the time of the study. RR is an employee of Gilead Sciences. All other authors declare no competing interests.Funding StatementThis work was supported by the National Institute of Health grants NIAID R43AI174349 (PI Lin), R43AI167169 (PI Lin), and R56AI179574 (MPIs Lau, Guo, and Su).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained and in accordance with the guidelines of the Institutional Review Board of Beth Israel Deaconess Medical Center, the Committee on Clinical Investigations (CCI). The CCI is charged with safeguarding the rights and welfare of human subjects by making determinations that gave ethical approval for this work. This study was conducted in accordance with both the Declarations of Helsinki and Istanbul.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors